Amwell delivered a strong Q1 2025, with total revenue reaching $66.8 million and significant improvement in net loss and Adjusted EBITDA. The company advanced its strategic initiatives, including progress with the Military Health System and improvements in revenue quality and cost alignment, moving closer to its goal of achieving cash flow breakeven from operations in 2026.
Total revenue for Q1 2025 was $66.8 million, showing growth compared to the previous year.
Net loss significantly improved to ($18.4) million from ($44.6) million in Q4 2024.
Adjusted EBITDA improved to ($12.2) million from ($22.8) million in Q4 2024.
The company reiterated its 2025 guidance for revenue and Adjusted EBITDA, and its objective to achieve positive cash flow from operations in 2026.
Amwell reiterated its full-year 2025 guidance for revenue and Adjusted EBITDA, and provided specific guidance for Q2 2025. The company remains committed to achieving positive cash flow from operations by 2026.
Analyze how earnings announcements historically affect stock price performance